Woebot Health, San Francisco, CA, USA.
Expert Rev Med Devices. 2022 Apr;19(4):287-301. doi: 10.1080/17434440.2022.2075726.
Postpartum Depression (PPD) is common, persistent, and stigmatized. There are insufficient trained professionals to deliver appropriate screening, diagnosis, and treatment.
WB001 is a Software as a Medical Device (SaMD) based Agent-Guided Cognitive Behavioral Therapy (AGCBT) program for the treatment of PPD, for which Breakthrough Device Designation was recently granted by the US Food and Drug Administration. WB001 combines therapeutic alliance, human-centered design, machine learning techniques, and established principles from CBT and interpersonal therapy (IPT). We introduce AGCBT as a new model of service delivery, whilst describing Woebot, the agent technology that enables guidance through the replication of some elements of human relationships. The profile describes the device's design principles, enabling technology, risk handling, and efficacy data in PPD.
WB001 is a dynamic and personalized tool with which patients may establish a therapeutic bond. Woebot is designed to augment (rather than replace) human healthcare providers, unlocking the therapeutic potency associated with guidance, whilst retaining the scalability and agency that characterizes self-help approaches. WB001 has the potential to improve both the quality and the scalability of care through providing support to patients on waiting lists, in between clinical encounters, and enabling automation of measurement-based care.
产后抑郁症（PPD）较为常见且具有持续性，同时还带有污名化。目前，接受过适当培训的专业人员数量不足，无法提供有效的筛查、诊断和治疗。
WB001 是一款基于软件的医疗设备（SaMD），是一款用于治疗 PPD 的代理指导认知行为疗法（AGCBT）程序，最近已被美国食品和药物管理局授予突破性设备指定。WB001 将治疗联盟、以人为本的设计、机器学习技术以及 CBT 和人际治疗（IPT）的既定原则相结合。我们将 AGCBT 作为一种新的服务交付模式进行介绍，同时描述了 Woebot，这是一种代理技术，通过复制人际关系的一些元素来实现指导。该产品描述了该设备在 PPD 中的设计原则、使能技术、风险处理和疗效数据。
WB001 是一款具有活力且个性化的工具，患者可以与它建立治疗关系。Woebot 的设计目的是增强（而不是取代）人类医疗保健提供者的作用，释放与指导相关的治疗效力，同时保留自助方法的可扩展性和自主性。通过为候诊患者、临床诊疗之间的患者以及实现基于测量的护理自动化提供支持，WB001 有潜力改善护理质量和可扩展性。
